https://www.selleckchem.com/products/icfsp1.html
0% versus 60.8% ( =0.918). The disease control rate was 96.9% in EGFR-TKI plus thymosin group and 97.7% in EGFR-TKI group ( =1.00. There were no significant differences in adverse effects between the two groups. The number of CD3 T cells in peripheral blood decreased significantly after treatment including both CD3 CD4 T and CD3 CD8 T subsets in EGFR-TKI group, but not in EGFR-TKI plus thymosin group. Combination of EGFR-TKI and thymosin can significantly prolong the PFS and OS compared with EGFR-TKI monotherapy without more adverse ev
Like
Comment
Share
